Novartis could face legal action over Zolgensma application
The pharmaceutical company failed to inform the FDA of manipulated data when the gene therapy was under review and could face a legal battle.
List view / Grid view
The pharmaceutical company failed to inform the FDA of manipulated data when the gene therapy was under review and could face a legal battle.
Less than one-third of UK patient groups rate the reputation of the pharma industry as good or excellent.
Researchers have detailed recent breakthrough experiments that successfully immunised mice against the Candida auris infection.
The Philippines is considering re-introducing a dengue vaccine whose use was ceased because of links to several deaths.
The EMA has requested that liposomal medication names be changed to avoid the risk of confusion.
New article says that to take full advantage of deep-learning solutions in healthcare, the US and China should collaborate, not compete.
Breakthrough Therapy Designation has been granted for investigational agent bempegaldesleukin in combination with nivolumab.
The rise of manufacturing advanced drugs will stimulate growth in the pharmaceutical chemical market.
The US supply of heparin, an ingredient used in anticoagulant drugs and found in pigs, is under threat due to an outbreak of disease in Chinese herds.
Lokelma, a treatment for hyperkalaemia in adults, has received a positive Final Appraisal Document from NICE after successful trials.
A fund of almost £450 million has been announced by the UK Government to mitigate drug shortages in the event of a no-deal Brexit.
Tecan Partnering has consolidated its extensive OEM system development services for life sciences and IVD instruments to create Tecan Synergence™.
A three-drug combination injection to treat patients with complicated urinary tract and intra-abdominal infections has been approved by the FDA.
The two Canadian provinces have expressed concern over the new draft regulations, claiming that the reforms would delay patient access to medicines.
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.